Healthcare Business

Agio Pharma Sinks on Midstage Trial

Agio Pharmaceuticals Inc. (NASDAQ: AGIO) saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia ...
Read Full Story »

Cara Therapeutics Wins Big on FDA Breakthrough

Cara Therapeutics Inc. (NASDAQ: CARA) saw its shares make a handy gain on Friday after the company said that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy ...
Read Full Story »

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Biotech companies are known for having a high-risk high-reward relationship. The health care sector as a whole has been very positive for investors over the past year, leading some analysts ...
Read Full Story »

Clovis Looks to Cash in on Secondary Offering

Shares of Clovis Oncology Inc. (NASDAQ: CLVS) saw a handy gain in Wednesday’s session after the company priced its secondary offering. This offering comes on the heels of a massive ...
Read Full Story »

Does Eiger BioPharmaceuticals Really Have 400% Upside?

Liana Moussatos of Wedbush Securities assumed coverage of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) with an Outperform rating. The old price target of $28 was also ratcheted up to $34. What ...
Read Full Story »

Neos Therapeutics Slides Despite FDA Approval

Neos Therapeutics Inc. (NASDAQ: NEOS) saw its shares dip on Tuesday after the firm reported that it received approval from the U.S. Food and Drug Administration (FDA) for its treatment ...
Read Full Story »

Large Insider Buying at Alexion Raises Investors’ Eyebrows

Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) fits that bill despite having a $26.5 billion market cap. Is ...
Read Full Story »

Egalet Stumbles Over FDA Complete Response Letter

Egalet Corp. (NASDAQ: EGLT) saw its shares take a dive early on Tuesday after the company announced that it received a complete response letter (CRL) from the U.S. Food and ...
Read Full Story »

Dova Pharmaceuticals Closes in on IPO

Dova Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 4.06 million shares ...
Read Full Story »

Akcea Therapeutics Announces Potential Pricing for IPO

Akcea Therapeutics has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 9.62 million ...
Read Full Story »

Rigel Pharma Rises Following FDA Approval

Shares of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) saw a handy uptick on Monday after the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for the use ...
Read Full Story »

Is This the Buyout Novadaq Needs?

Novadaq Technologies Inc. (NASDAQ: NVDQ) watched its shares practically double to kick off the week after the firm announced that it would be acquired by Striker Corp. (NYSE: SYK). The ...
Read Full Story »

Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial

Clovis Oncology Inc. (NASDAQ: CLVS) saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 Ariel3 trial of rucaparib ...
Read Full Story »

Aurinia Pharma Rises Following Updated Mid-Stage Results

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) saw a handy gain on Friday after the firm presented new data from its mid-stage study in lupus nephritis (LN) during the Annual ...
Read Full Story »

Mersana Therapeutics Closes in on IPO After Announcing Expected Price Range

Mersana Therapeutics has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 5.0 million ...
Read Full Story »